Interferon-gamma plus camrelizumab with chemotherapy before surgery for locally advanced esophageal squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional study investigates a neoadjuvant regimen combining interferon-gamma, camrelizumab, and chemotherapy for locally advanced esophageal squamous cell carcinoma. Eligible adults with biopsy-confirmed ESCC, staged cT1b-3 N+ M0, and good performance status will receive the combination therapy prior to surgical resection. Primary goals include assessing safety and preliminary efficacy to determine if this approach can improve surgical outcomes and disease control. The trial will monitor adverse events, response to therapy, and perioperative considerations to inform future research. Lead sponsorship is from Hefei Cancer Hospital of the Chinese Academy of Sciences, with two Anhui-based sites participating.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged \>= 18 years;
2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
4. Expected overall survival \> 6 months;
5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function.

Exclusion Criteria:

1. Active autoimmune disease;
2. Requirement for systemic immunosuppressive therapy;
3. Hypersensitivity to any study drug;
4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection;
5. Pregnant or lactating female.

Where it's running

• Hefei Cancer Hospital, Chinese Academy of Sciences
  Hefei, Anhui, China Recruiting
• The First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Hongzhi Wang
• Email: wanghz@hfcas.ac.cn
• Phone: +86 551 6589 5180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma

  This trial tests whether giving camrelizumab with chemotherapy and the JAK inhibitor Ivarmacitinib before surgery can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma that can be removed by operation.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT07505186

• Combining TACE with Camrelizumab and Apatinib for Liver Cancer

  This study is testing if combining a liver cancer treatment called TACE with two drugs, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better compared to standard treatments.

  Recruiting Phase 3 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06485466

• Cadonilimab with paclitaxel micelles and cisplatin before surgery for locally advanced esophageal squamous cancer

  This trial will test whether giving cadonilimab together with paclitaxel polymeric micelles and cisplatin before surgery helps people with locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06356688

• Combining camrelizumab with chemotherapy for lung cancer treatment

  This study is testing if combining a new drug called camrelizumab with chemotherapy can help people with certain types of lung cancer before surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06241807

• Combination therapy for high-risk acral melanoma before surgery

  This study is testing a new combination of treatments before surgery to see if it can help people with high-risk acral melanoma have better outcomes.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05512481

• Combining Camrelizumab with TCb for treating triple-negative breast cancer

  This study is testing if combining a new drug called camrelizumab with a chemotherapy treatment can help people with triple-negative breast cancer do better after surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05475678

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.